IAA
CRSP icon

Independent Advisor Alliance’s CRISPR Therapeutics CRSP Stock Holding History

Independent Advisor Alliance’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
8,844
+937
+12% +$49.4K 0.01% 677
2026
Q1 		$376K Buy
7,907
+585
+8% +$30.9K ﹤0.01% 1229
2025
Q4 		$384K Sell
7,322
-118
-2% -$7.07K 0.01% 724
2025
Q3 		$482K Sell
7,440
-267
-3% -$15.3K 0.01% 631
2025
Q2 		$375K Sell
7,707
-241
-3% -$9.33K 0.01% 668
2025
Q1 		$270K Buy
7,948
+167
+2% +$7.08K 0.01% 685
2024
Q4 		$306K Buy
7,781
+62
+0.8% +$2.93K ﹤0.01% 1133
2024
Q3 		$363K Buy
7,719
+1,745
+29% +$88.5K 0.01% 524
2024
Q2 		$323K Buy
5,974
+80
+1% +$4.63K 0.01% 555
2024
Q1 		$402K Buy
5,894
+532
+10% +$38.1K 0.01% 500
2023
Q4 		$336K Sell
5,362
-9,894
-65% -$547K 0.01% 523
2023
Q3 		$692K Buy
15,256
+11,685
+327% +$603K 0.03% 353
2023
Q2 		$200K Buy
+3,571
New +$203K 0.01% 625
2022
Q2 		– Sell
-3,842
Closed -$241K – 641
2022
Q1 		$241K Buy
3,842
+1,011
+36% +$63.5K 0.01% 555
2021
Q4 		$215K Buy
+2,831
New +$247K 0.01% 614

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Independent Advisor Alliance's CRSP Position: Q2 2026 in Review

Independent Advisor Alliance increased its CRISPR Therapeutics (CRSP) stake by 12% in Q2 2026, buying an estimated $49.4K and bringing the position to 8,844 shares worth $482K. The position accounts for 0.01% of the portfolio, ranked #677.

Independent Advisor Alliance first reported a position in CRSP in Q4 2021 and has held it in 15 quarters since. The position peaked at $692K in Q3 2023. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Independent Advisor Alliance held 8,844 shares of CRISPR Therapeutics worth $482K as of Q2 2026.
  • Independent Advisor Alliance bought 937 CRISPR Therapeutics shares in Q2 2026, an estimated $49.4K.
  • CRISPR Therapeutics made up 0.01% of Independent Advisor Alliance's portfolio in Q2 2026, its #677 holding.
  • Independent Advisor Alliance first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Independent Advisor Alliance's CRISPR Therapeutics position peaked at $692K in Q3 2023.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Independent Advisor Alliance's 13F filing for Q2 2026, filed 12 Aug 2026.